belumosudil 200 MG Oral Tablet

RxCUI
2564031
RxNorm name
belumosudil 200 MG Oral Tablet
Display name
belumosudil 200 MG Oral Tablet
Full name
belumosudil 200 MG Oral Tablet
Term type
PSN
Status
DailyMed mapping
Updated
2026-06-04 23:38:47

RxNav Current And Historical NDCs#

RxNav current and historical NDC rows page 1 of 1 · 0 matching rows.

No records found.

UNII Substances#

UNII substance links page 1 of 1 · 0 matching rows.

No records found.

openFDA label cross-check#

Cross-check layer: openFDA label JSON enriches search and identifies hydration gaps. The DailyMed Structured Product Label remains the canonical label presentation on FDA.report. Every label matching the complete exact-identifier union is deduplicated and paginated below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
RezurockBELUMOSUDILKadmon Pharmaceuticals, LLC102e4ef4-7f84-4e34-8df1-479c24d1575d2026-04-07Warnings, Adverse reactionsExact identifier
rxcui: 2564031

DailyMed RxNorm Mappings#

Set ID, RxNorm string, TTY table
Set IDRxNorm stringTTYSPL versionLabelEffective
102e4ef4-7f84-4e34-8df1-479c24d1575dbelumosudil 200 MG Oral TabletPSN11These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK. REZUROCK ® (belumosudil) tablets, for oral use Initial U.S. Approval: 202120260407
102e4ef4-7f84-4e34-8df1-479c24d1575dbelumosudil 200 MG Oral TabletSCD11These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK. REZUROCK ® (belumosudil) tablets, for oral use Initial U.S. Approval: 202120260407
102e4ef4-7f84-4e34-8df1-479c24d1575dbelumosudil (as belumosudil mesylate) 200 MG Oral TabletSY11These highlights do not include all the information needed to use REZUROCK safely and effectively. See full prescribing information for REZUROCK. REZUROCK ® (belumosudil) tablets, for oral use Initial U.S. Approval: 202120260407